Search Results

Proteros biostructures GmbH announced a new collaboration with Orion Corporation.

Proteros biostructures GmbH announced that it has initiated a multi-target drug discovery partnership with Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases.

Proteros biostructures GmbH, an expert in integrated structure-based drug discovery, announces an expansion of its collaboration with AstraZeneca focused on the discovery and development of novel epigenetic drugs.

MARTINSRIED, Germany and MUNICH, Germany, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Proteros biostructures GmbH , a leading German-based, founder-led contract research organization focused on early-stage drug discovery today announced that it has received a minority investment from Inflexion, a leading middle-market private equity firm investing in high-growth, entrepreneurial businesses, by way of partnership capital funding. The transaction is subject to customary regulatory approvals and is expect

Adrestia Therapeutics announced the appointment of Dr James Osborne as Head of Chemistry and the initiation of a multi-target partnership with Proteros biostructures GmbH to accelerate the discovery of first-in-class candidate drugs for intractable diseases.

Helix Biostructures offers a full gene-to-structure suite of cryo-EM services that focuses on both quality and fast turnaround/throughput.

ORTHOSON, a medtech innovator developing a portfolio of novel treatments for back pain, today announced that its Bio-Structural Gel product has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).

Great Point Partners, a Greenwich-based investment firm focused exclusively on the health care industry, announced the acquisition of Lyocontract GmbH, a premium independent drug product contract development and manufacturing organization based in Ilsenburg, Germany.